Previous 10 | Next 10 |
Celldex stock rose sharply after CDX-0159 data was announced in June. CDX-527 Phase 1 trial is now underway. Topline CD-3379 Phase 2 data should arrive before year-end. For further details see: Why Celldex Has Been A Big Winner In 2020
Gainers: Genfit (GNFT) +35%, Trxade Group (MEDS) +20%, Celldex Therapeutics (CLDX) +15%, EDAP TMS (EDAP) +13%, Kaleido Biosciences (KLDO) +8%.Losers: Abeona Therapeutics (ABEO) -33%, Aquestive Therapeutics (AQST) -35%, Mallinckrodt (MNK)&...
HAMPTON, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside Chats at the Cantor Virtual Global Healthcare Conference and the HC Wainwright & CO 22nd Annual Global Investment Virtual Conference. ...
Celldex Therapeutics ( CLDX ) recently held its first quarterly call since releasing highly promising Phase I data on CDC-0159 — its novel mast cell blocking antibody, reports John McCamant , biotech sector expert and editor of The Medical Technology Stock Letter . ...
Tricida suffers setback on Veverimer front Tricida Inc. ( TCDA ) reported that the FDA has given a Complete Response Letter to the company for its application pertaining to Veverimer. The New Drug Application for the drug candidate was being reviewed under the Accelerated Approval Progra...
Celldex Therapeutics ( CLDX +2.5% ) has opened enrollment for its Phase 1 study of CDX-527 in metastatic solid tumors, whose disease have progressed during or after standard of care therapy. More news on: Celldex Therapeutics, Inc., Healthcare stocks news, Read more ...
HAMPTON, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label, Phase 1 study of CDX-527 in patients with advanced or metastatic solid tumors that have progressed during or after standard of care therapy...
Celldex Therapeutics, Inc. (CLDX) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Sarah Cavanaugh – Senior Vice President, Corporate Affairs and Administration Anthony Marucci – Co-founder, President and Chief Executive Officer Diane ...
Celldex (NASDAQ: CLDX ) : Q2 GAAP EPS of -$0.50 beats by $0.08 . More news on: Celldex Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
HAMPTON, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2020. The Company will host a conference call at 4:30 p.m. ET today to provide an update on its pipeline and upcom...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...